Lybrido was the first product we developed for the treatment of HSDD. It proved effective for women with low sex drive and motivation as a result of insensitivity to sexual cues.
Lybrido increases central sexual motivation and physiological sexual response, such as swelling of vaginal erectile tissue and lubrication.
However, in our studies we found that Lybrido was not effective in the subgroup of women who suffer from HSDD as a result of inhibitory mechanisms. We depart from the assumption that these women can be aroused, but negative associations with sex – as a result of past experiences, for instance – trigger an inhibitory reflex in the brain.
For the effective treatment of this second group, we subsequently developed Lybridos.